
2019美国癌症研究协会(AACR)年会—新药前瞻 - 知乎
大型多功能肽酶7(LMP7)也称为β5i或PSMB8,是免疫蛋白酶体(immunoproteasome)中一种类似糜蛋白酶的蛋白水解亚基,能够降解 泛素化 蛋白并产生呈递给 MHCⅠ 的多肽。
Immunoproteasome subunit LMP7 Deficiency Improves …
2015年10月30日 · Low-molecular mass protein-7 (LMP7) is a proteolytic subunit of the immunoproteasome that shapes the repertoire of antigenic peptides on major histocompatibility...
The Immunoproteasome Subunits LMP2, LMP7 and MECL-1 …
2021年4月21日 · In summary we provide evidence for a critical role of the IP subunits β1i/LMP2, β2i/MECL-1 and β5i/LMP7 for the control of cerebral Toxoplasma gondii infection and subsequent neuroinflammation.
PSMB8/LMP7 (1A5) Mouse mAb #13726 - Cell Signaling …
PSMB8/LMP7 (1A5) Mouse mAb recognizes endogenous levels of total PSMB8/LMP7 protein. This antibody recognizes both 28 kDa precursor and 23 kDa mature forms of PSMB8/LMP7 and does not cross-react with PSMB5 protein.
Immunoproteasome subunit LMP7 deficiency and inhibition …
2012年10月15日 · LMP7 governs Th cell lineage determination by affecting the balance of receptor proximal signals during differentiation. These data render LMP7 a promising drug target for the treatment of autoimmune diseases. The immunoproteasome generates peptides presented on MHC class I molecules to cytotoxic T cells.
免疫蛋白酶体选择性抑制剂的抗肿瘤活性。,Blood - X-MOL
2007年11月16日 · 在造血细胞中占主导地位的免疫蛋白酶体包含独特的活性位点亚基 LMP7、LMP2 和 MECL1,分别具有胰凝乳蛋白酶样、半胱天冬酶样和胰蛋白酶样活性。 蛋白酶体抑制剂硼替佐米和卡非佐米已证实蛋白酶体可作为血液系统恶性肿瘤的治疗靶点;然而,这些抑制剂同时针对组成型和免疫蛋白酶体。 我们假设免疫蛋白酶体的选择性抑制将对血液肿瘤具有抗肿瘤活性,并且可以避免与组成型蛋白酶体抑制相关的毒性。 方法:血液学恶性细胞中免疫蛋白酶体 …
Inhibition and deficiency of the immunoproteasome subunit LMP7 …
Since the immunoproteasome promotes Th1 and Th17 differentiation and pro-inflammatory cytokine production, we investigated here whether deficiency or inhibition of the immunoproteasome subunit LMP7 would interfere with CRC development and exacerbation in preventive and therapeutic mouse models.
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is ... - PubMed
Here, we show that PRN1126, developed as an exclusively LMP7-specific inhibitor, has limited effects on IL-6 secretion, experimental colitis, and experimental autoimmune encephalomyelitis (EAE). We demonstrate that prolonged exposure of cells with ONX 0914 leads to inhibition of both LMP7 and LMP2.
Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 ...
2021年1月20日 · We found that the expression of the immunoproteasome catalytic subunit, large multifunctional protease 2 (LMP2), was significantly upregulated in peripheral blood mononuclear cells of active ITP patients compared to those of healthy controls. No significant differences in LMP7 expression were observed between patients and controls.
MHC-encoded proteasome subunits LMP2 and LMP7 are not …
1994年2月1日 · LMP2 and LMP7 are subunits of a subset of proteasomes, large molecular assemblies with multi-proteolytic activities believed to degrade damaged and unwanted cellular proteins. Like TAP and class I molecules themselves, expression of LMP genes is enhanced after exposure of cells to IFN-gamma.